FDA Approves Deucravacitinib for Adults with Active Psoriatic Arthritis

FDA approves deucravacitinib for adults with active psoriatic arthritis

The FDA has approved deucravacitinib for adults with active psoriatic arthritis, according to a press release from Bristol Myers Squibb. Deucravacitinib (Sotyktu), an oral, selective tyrosine kinase 2 (TYK2) inhibitor has already received FDA approval for adults with moderate-to-severe plaque psoriasis.

BMS gains FDA approval for Sotyktu in psoriatic arthritis treatment

BMS has received the US FDA approval for Sotyktu, an oral selective TYK2 inhibitor, to treat adults with active psoriatic arthritis (PsA).The post BMS gains FDA approval for Sotyktu in psoriatic arthritis treatment appeared first on Hospital Management.